Briefing
NCCN 2026 non-clear-cell RCC update asks clinicians to consider tumor genomic testing for trials
The 2026 NCCN kidney cancer discussion added a recommendation, for non-clear-cell renal cell carcinoma, to consider tumor genomic testing for clinical-trial eligibility.